U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C41H36ClF3N2O4S
Molecular Weight 745.249
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GIRIPLADIB

SMILES

OC(=O)C1=CC=C(CCCC2=C(CCNS(=O)(=O)CC3=CC=CC=C3C(F)(F)F)N(C(C4=CC=CC=C4)C5=CC=CC=C5)C6=CC=C(Cl)C=C26)C=C1

InChI

InChIKey=NHHBNHIPCSPSHQ-UHFFFAOYSA-N
InChI=1S/C41H36ClF3N2O4S/c42-33-22-23-37-35(26-33)34(16-9-10-28-18-20-31(21-19-28)40(48)49)38(47(37)39(29-11-3-1-4-12-29)30-13-5-2-6-14-30)24-25-46-52(50,51)27-32-15-7-8-17-36(32)41(43,44)45/h1-8,11-15,17-23,26,39,46H,9-10,16,24-25,27H2,(H,48,49)

HIDE SMILES / InChI

Molecular Formula C41H36ClF3N2O4S
Molecular Weight 745.249
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Giripladib (PLA 695) is a Cytosolic phospholipase A2 (cPLA2) inhibitor. cPLA2 is associated with tumor progression and radioresistance in mouse tumor models. In these models, treatment with giripladib attenuates radiation induced increases of phospho-ERK and phospho-Akt in endothelial cells. Combined with irradiation, giripladib reduces migration and proliferation in endothelial cells (HUVEC & bEND3) and induces cell death and attenuated invasion by tumor cells (LLC &A549). The combination treatment of giripladib and irradiation also delayes growth in both LLC and A549 tumors and results in reduced tumor vasculature. Phase I studies have been conducted to test the gastrointestinal safety of giripladib, and potential pharmacokinetic interaction with other compounds. A phase II study was terminated.

Approval Year

Substance Class Chemical
Created
by admin
on Fri Dec 15 18:27:49 GMT 2023
Edited
by admin
on Fri Dec 15 18:27:49 GMT 2023
Record UNII
1W10Q5H7WD
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GIRIPLADIB
INN   USAN  
INN   USAN  
Official Name English
PLA-695
Code English
giripladib [INN]
Common Name English
4-[3-[5-Chloro-1-(diphenylmethyl)-2-[2-[[[2-(trifluoromethyl)benzyl]sulfonyl]amino]ethyl]-1H-indol-3-yl]propyl]benzoic acid
Systematic Name English
GIRIPLADIB [USAN]
Common Name English
Code System Code Type Description
PUBCHEM
11721842
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
INN
8810
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
EPA CompTox
DTXSID00471130
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
ChEMBL
CHEMBL2104969
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
FDA UNII
1W10Q5H7WD
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
NCI_THESAURUS
C166518
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
DRUG BANK
DB15426
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
USAN
SS-27
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
SMS_ID
300000034212
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
CAS
865200-20-0
Created by admin on Fri Dec 15 18:27:49 GMT 2023 , Edited by admin on Fri Dec 15 18:27:49 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY